Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 12/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25798588 | 0.87 | IL1B (0.62) | IL1BNLRP3 | |
| SCHEMBL25797912 | 0.82 | IL1B (0.72) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL25798971 | 0.80 | IL1B (0.51) | IL1BNLRP3KCNH2TNFCCNT1 | |
| SCHEMBL25798372 | 0.78 | IL1B (0.68) | IL1BNLRP3 | |
| SCHEMBL25798270 | 0.78 | IL1B (0.65) | IL1BNLRP3 | |
| SCHEMBL25798976 | 0.78 | IL1B (0.61) | IL1BNLRP3 | |
| SCHEMBL25798115 | 0.72 | IL1B (0.62) | IL1BNLRP3 | |
| SCHEMBL25798433 | 0.72 | NLRP3 (0.60) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31021456 | 0.71 | IL1B (0.67) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31021530 | 0.71 | IL1B (0.57) | IL1BNLRP3KCNH2TNFCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129987-A1 | PYRIDAZINE DERIVATIVES AS MODULATORS OF NLRP3 INFLAMMASOME AND RELATED METHODS | Neumora Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |